Good news for those that suffer from psoriasis – a chronic, inflammatory genetic immune condition. A new biologic COSENTYX was just approved by the FDA for the treatment of moderate to severe psoriasis.
This medication works by blocking a specific component of the immune system called IL-17. By doing so, the drug decreases inflammation caused by psoriasis and improves the patients skin. In studies. over 65% of patients were clear or almost clear after 12 – 16 weeks of treatment.
While like all systemic medications, cosentyx has some potential side effects, with careful lab monitoring and follow up, the drug can be used safely.
Other Blog Entries: